T33	Exp 172 186	The activation
T34	Exp 345 347	we
T35	Exp 326 343	the present study
T36	Exp 384 398	the regulation
T37	Exp 417 442	the mRNA or protein level
T38	Exp 458 488	the age-associated impairments
T39	Exp 622 636	the lectin PHA
T40	Exp 711 725	the expression
T41	Exp 869 873	that
T42	Exp 1096 1106	the levels
T43	Exp 1150 1178	the AP-1 consensus TRE motif
T44	Exp 1180 1198	the proximal c-jun
T45	Exp 1230 1262	the c-fos serum response element
T46	Exp 1329 1344	the stimulation
T47	Exp 1447 1459	the AP-1 TRE
T48	Exp 1533 1547	the activation
T49	Exp 1652 1681	the nuclear protein complexes
T50	Exp 1690 1703	the SRE motif
T51	Exp 1844 1858	the activation
T52	Exp 2017 2050	their nuclear regulatory proteins
T53	Exp 1946 1950	that
T54	Exp 1977 1990	the induction
T55	Exp 2069 2096	the age-related impairments
T56	Exp 1924 1937	These results
R7	Coref Anaphora:T52 Antecedent:T57
T1	Protein 22 27	c-fos
T2	Protein 28 33	c-jun
T3	Protein 100 105	c-fos
T4	Protein 106 111	c-jun
T5	Protein 213 218	c-Fos
T6	Protein 219 224	c-Jun
T7	Protein 402 407	c-fos
T8	Protein 408 413	c-jun
T9	Protein 585 595	CD3epsilon
T10	Protein 633 636	PHA
T11	Protein 685 690	c-Fos
T12	Protein 729 734	c-Fos
T13	Protein 743 748	c-Jun
T14	Protein 986 991	c-fos
T15	Protein 999 1004	c-jun
T16	Protein 1193 1198	c-jun
T17	Protein 1234 1239	c-fos
T18	Protein 1461 1466	c-jun
T19	Protein 1476 1481	c-fos
T20	Protein 1596 1601	c-jun
T21	Protein 1610 1615	c-fos
T22	Protein 1773 1794	serum response factor
T23	Protein 1799 1804	Elk-1
T24	Protein 1912 1917	c-jun
T25	Protein 1994 1999	c-fos
T26	Protein 2000 2005	c-jun
T57	Exp 1951 1973	underlying aberrancies
